CD47 and cancer: Moreover, Weiping Li et al. found that compared with using bromodomain extraterminal inhibitors (BETi) (JQ1, I-BET, and OTX015), which can downregulate CD47 expression, the therapeutic strategy with BETi and the BCL-2 antagonist ABT-199 could more effectively inhibit the expression of MYC and CD47 and significantly reduce cancer cell proliferation [83].